Antibody Therapeutics for Life

Notices

PharmAbcine, to Present in KABSP-SF 2020, San Francisco
  • Written by PharmAbcine
  • Written date 2020-01-03 09:07:26
  • Inquire 145

PharmAbcine Inc. (KOSDAQ: 208340), will participate in the KABSP-SF 2020 held at the Hilton SF Airport on January 11 in San Francisco,California. 

As one of active members of KABSP, PharmAbcine sponsors the KABSP-SF 2020 Symposium and Dr. Jin-San Yoo (CEO) will present at the symposium on 

January 11, 2020. During the presentation, Dr. Jin-San Yoo will highlight recent remarks of company’s clinical and pre-clinical pipelines and its achievements. 

The detail of presentation are as follows:

 

Date: January 11, 2020

Time: 11:30 AM PST

Track: Embassy Suites

Venue: Hilton SF Airport, San Francisco

 

PharmAbcine is looking to attain a talent pool for prospective candidates by holding an on-site job interview at the KASBP-SF.

 

KASBP (Korean American Society in Biotech and pharmaceuticals) is a non-profit organization for Korean-American professionals in life-sciences, biotech and 

pharmaceutical fields. The purpose of KASBP is to promote strategic partnership among the members in the life science related fields such that it can ultimately 

help the members to achieve drug discovery and drug development and exchange in information and technologies among Korean and US companies. During 

the symposium, KASBP also holds a panel discussion with invited experts to share up-to-date information and their professional expertise, and posts employment 

information for job seekers and employers.

 

For more information about the KASBP-SF 2020 Symposium, please visit the website: https://www.kasbpsf.org/

 

About PharmAbcine Inc.

 

PharmAbcine is a clinical-stage biotech company focusing on the development of fully human antibody (mAb) therapeutics, especially reputed for leading the 

development of next-generation multi-specific antibodies. This multi-specific antibody technology can be achieved through our in-house novel technology 

development, namely DIG-Body, PIG-Body and TIG-Body. Using innovative discovery technology and excellent human resources, we provide a number of 

superlative immunotherapeutics for indications in immuno-oncology, immunology and ophthalmology.

 

PharmAbcine’s HuPhage library and innovative selection system are priceless proprietary assets. Additionally, our well-established 3G expression system 

ultimately helped concrete our stupendous reputation in the field of biopharma industry by allowing us to achieve the reinforcement and reproducibility of high 

levels of antibody production. On the basis of its highly maintained, advanced technical systems, we provide high quality antibody generation services. 

Moreover, our high standards antibodies have allowed us to be actively involved in co-development with our partners and we are willing to expand co-development 

opportunities to other potential partners.

 

Under the collaboration with SAMSUNG MEDICAL CENTER, we have more than 300 patients-derived cancer stem cell libraries and an animal model 

system for evaluating internal pipeline development.

List





Prev PharmAbcine, Korea-Europe Gathering for Open Innovation_KDHI
Next PharmAbcine, to Participate in Both J.P. Morgan Health Conference 2020 and Biote...